Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Operating expense | 6.9M | 13.4% |
| Net Income | -6.6M | 13.6% |
| EBITDA | -6.6M | 8.9% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 32M | 7.6% |
| Total Liabilities | 6.2M | 14.5% |
| Total Equity | 26M | 5.8% |
| Shares Outstanding | 99M | 12.3% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | -7.3M | 19.2% |
| Cash from financing | 4.2M | 82.1% |
EPS
Financial Highlights for Sellas Life Sciences Group in Q2 '25
Operating Expenses for this period were 6.9M, showing a 13.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -6.6M, showing a -13.6% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -6.6M, showing a -8.9% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Sellas Life Sciences Group faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
